Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer

PURPOSE: Some gastric cancers harbor MET gene amplifications that can be targeted by selective MET inhibitors to achieve tumor responses, but resistance eventually develops. Savolitinib, a selective MET inhibitor, is beneficial for treating patients with MET-driven gastric cancer. Understanding the...

Descripción completa

Detalles Bibliográficos
Autores principales: Frigault, Melanie M., Markovets, Aleksandra, Nuttall, Barrett, Kim, Kyoung-Mee, Park, Se Hoon, Gangolli, Esha A., Mortimer, Peter G.S., Hollingsworth, Simon J., Hong, Jung Yong, Kim, Kyung, Kim, Seung Tae, Barrett, J. Carl, Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446425/
https://www.ncbi.nlm.nih.gov/pubmed/32923890
http://dx.doi.org/10.1200/PO.19.00386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446425/
https://www.ncbi.nlm.nih.gov/pubmed/32923890
http://dx.doi.org/10.1200/PO.19.00386

Ejemplares similares